Form 4: IDEAYA Biosciences Director Acquires Stock Options

IDEAYA Biosciences Director Scott W. Morrison acquired 20,000 stock options with an exercise price of $30.57, vesting under specific conditions.

Summary

• Scott W. Morrison, a Director at IDEAYA Biosciences, Inc., acquired 20,000 stock options on June 16, 2026.
• The options have an exercise price of $30.57 and are exercisable until June 16, 2036.
• Vesting of these options is contingent upon the Reporting Person continuing in service on the Board through the vesting date, with full vesting occurring on the first anniversary of the grant date or immediately prior to the Annual Meeting following the grant date, whichever is earlier.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider option grant rather than a significant new development or financial event.

Positives

• Director acquisition of stock options signals confidence in the company's future prospects.
• The acquisition of 20,000 options indicates a significant commitment from a key insider.

Risks

• Vesting of options is subject to continued service, meaning the director could forfeit them if they leave the board.
• The exercise price of $30.57 implies that the stock price needs to increase significantly for the options to be profitable.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future performance, as the value of these options is tied to the stock price appreciation.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector, reflecting the high-risk, high-reward nature of drug development and the need to incentivize key personnel.

Stakeholder Impact

• Shareholders may view this as a positive signal of insider confidence, potentially supporting share price.
• Employees may be motivated by the continued commitment of leadership.
• Creditors and suppliers are unlikely to be directly impacted by this transaction.

Next Steps

• The director will continue to serve on the Board to meet vesting conditions.
• The options may be exercised if the stock price exceeds $30.57 before their expiration in 2036.

Key Dates

Recommendation

This filing is a routine Form 4 indicating the grant of stock options to a director. It does not contain new financial results, strategic shifts, or significant corporate events that would warrant a change in investment recommendation. The value of the options is contingent on future stock performance.

Keywords

IDEAYA Biosciences, IDYA, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, Securities Exchange Act